RYAN vs VRTX · P/E 43, rev $2.46B vs P/E 30, rev $12.00B
Ryan Specialty Group Holdings Inc (RYAN) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Ryan Specialty Group Holdings Inc (RYAN) is a insurance - specialty company listed on NYSE.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported RYAN revenue for 2024-12-31 was $2.46B. Net income was $229.9M. Revenue was up 21.2% from 2023-12-31 to 2024-12-31. RYAN currently screens at market cap $9.33B and trailing P/E 43.1.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
RYAN currently screens at market cap $9.33B and trailing P/E 43.1. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the RYAN and VRTX stock pages for the full models.
Not investment advice.